Rohinton S. Tarapore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rohinton S. Tarapore has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Carl Koschmann
Department of Pediatrics, University of Michigan Medical School , Ann Arbor, Michigan
61 shared publications - Cassie Kline
Division of Oncology The Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
60 shared publications - Joshua E. Allen
Chimerix, Inc 27713 Durham NC
60 shared publications - Sharon L. Gardner
New York University, New York, NY, USA
60 shared publications - Yazmin Odia
Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA; Department of Neuro-Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
60 shared publications - Ashley Sumrall
Levine Cancer Institute, Charlotte, NC
59 shared publications
Latest Publications
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.